Kezdőlap・Részvénylista・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

56.55 3.91

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

53.84

Maximum

55.23

Fő mutatók
By Trading Economics
Bevétel	-22M -115M
Értékesítés	22M 268M
Egy részvényre jutó nyereség	-0.7
Profit margin	-42.787
Munkavállalók	1,480
EBITDA	-37M -105M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+66.32% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. okt. 28.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-193M 9.1B
Előző nyitás	52.64
Előző zárás	56.55

Hangulat hírek alapján

By Acuity

100%

329 / 340 Rangsor szerint Healthcare

Ionis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 6. 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

2026. aug. 5. 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

2026. aug. 4. 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

2026. aug. 3. 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

2026. aug. 1. 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

2026. júl. 31. 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

2026. júl. 30. 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

2026. júl. 29. 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

2026. júl. 28. 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

2026. júl. 27. 20:07 UTC

News

Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

2026. júl. 25. 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

2026. júl. 24. 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

2026. júl. 23. 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

2026. júl. 22. 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

2026. júl. 21. 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

2026. júl. 20. 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Társak összehasonlítása

Árváltozás

Ionis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

66.32% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 90.13 USD 66.32%

Magas 115 USD

Alacsony 68 USD

18 Wall Street elemző 12 hónapos célárain alapulva a(z)Ionis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

18 ratings

Vétel

Tartás

Eladás

18 Wall Street elemző célárain alapulva a(z)Ionis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.